Skip to main content
Erschienen in: Archives of Osteoporosis 1/2020

01.12.2020 | Original Article

Outcome of osteoporosis evaluation, treatment, and follow-up in patients referred to a specialized outpatient clinic compared to patients in care of general practitioners

verfasst von: Mette Friberg Hitz, Sofie Arup, Jakob Praest Holm, Anne Lyngholm Soerensen, Thomas Alexander Gerds, Jens-Erik Beck Jensen

Erschienen in: Archives of Osteoporosis | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Summary

In Denmark, osteoporosis treatment is either handled by general practitioners or at more resource demanding specialist clinics. We evaluated the treatment adherence and persistence in the two settings, which were overall similar. The type of medical support did, however, differ and was provided to two very different patient populations.

Purpose

The study aimed to investigate the effect of patient care by general practitioners (GPs) or specialists on treatment adherence among osteoporosis patients initiating treatment with oral bisphosphonates (OB).

Methods

Dual-energy X-ray absorption (DXA)-scanning data from 2005 to 2013 were extracted. Treatment naïve patients with a T-score ≤ − 2.5 (spine or hip) were included. Information on medical treatment, comorbidities, and socio-economic status was extracted from Danish registries. Scanning results were evaluated by a specialist. Subsequent treatment initiation and follow-up was either handled by GPs or specialists: GP population (GPP) vs. specialist population (SP). Primary adherence was defined as treatment initiating within 12 months from diagnosis and secondary adherence as days with medicine possession rates (MPR) > 80%.

Results

Of 11,201 DXA-scanned patients, 3685 met the inclusion criteria (GPP = 2177, SP = 1508). The GPP consisted of relatively more men, was older, had shorter education, lower income, and more comorbidities. There was no difference in baseline T-score or prior incidence of major osteoporotic fractures (MOFs). The GPP was primarily treated with OB and had better primary adherence (adjusted ORGPP/SP = 1.52 [1.31–1.75], p < 0.0001) than the SP that to a higher degree received another treatment. Secondary adherence was similar (adjusted ORGPP/SP: OR12 months = 1.02 [0.83–1.26]; OR24 months = 0.90 [0.73–1.10]; OR4 years = 0.88 [0.71–1.07]; OR5 years = 0.91 [0.74–1.13].

Conclusion

Patients in care of specialists were most likely to receive a treatment other than OB. Primary adherence was highest in the GPP, whereas short- and long-term persistence was similar for up to 5 years whether treated by a specialist or a GP.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Yeam CT, Chia S, Tan HCC, Kwan YH, Fong W, Seng JJB (2018) A systematic review of factors affecting medication adherence among patients with osteoporosis. Osteoporos Int 12:2623–2637CrossRef Yeam CT, Chia S, Tan HCC, Kwan YH, Fong W, Seng JJB (2018) A systematic review of factors affecting medication adherence among patients with osteoporosis. Osteoporos Int 12:2623–2637CrossRef
2.
Zurück zum Zitat Osterberg L, Blaschke T (2005) Adherence to medication. NEJM 353:487–497CrossRef Osterberg L, Blaschke T (2005) Adherence to medication. NEJM 353:487–497CrossRef
3.
Zurück zum Zitat Maraka S, Kenrel KA (2015) Bisphosphonates for prevention and treatment of osteoporosis. BMJ 351:h3783CrossRef Maraka S, Kenrel KA (2015) Bisphosphonates for prevention and treatment of osteoporosis. BMJ 351:h3783CrossRef
4.
Zurück zum Zitat Cramer JA, Silverman S (2006) Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med 119(4A):12S–17SCrossRef Cramer JA, Silverman S (2006) Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med 119(4A):12S–17SCrossRef
5.
Zurück zum Zitat Cheen MHH, Tan YZ, Oh LF, Wee HL, Thumboo J (2019) Prevalence of and factors associated with primary medication non-adherence in chronic disease: a systematic review and meta-analysis. Int J Clin Pract 73(6):e13350CrossRef Cheen MHH, Tan YZ, Oh LF, Wee HL, Thumboo J (2019) Prevalence of and factors associated with primary medication non-adherence in chronic disease: a systematic review and meta-analysis. Int J Clin Pract 73(6):e13350CrossRef
6.
Zurück zum Zitat Reynolds K, Muntner P, Cheetham TC (2013) Primary non-adherence to bisphosphonates in an integrated healthcare setting. Osteoporos Int 24(9):2509–2517CrossRef Reynolds K, Muntner P, Cheetham TC (2013) Primary non-adherence to bisphosphonates in an integrated healthcare setting. Osteoporos Int 24(9):2509–2517CrossRef
7.
Zurück zum Zitat Chiu CK, Kuo MC, Yu SF, Su BY, Cheng TT (2013) Adherence to osteoporosis regimens among men and analysis of risk factors of poor compliance: a 2-year analytical review. BMC Musculoskelet Disord 14:276CrossRef Chiu CK, Kuo MC, Yu SF, Su BY, Cheng TT (2013) Adherence to osteoporosis regimens among men and analysis of risk factors of poor compliance: a 2-year analytical review. BMC Musculoskelet Disord 14:276CrossRef
8.
Zurück zum Zitat Lee S, Glendenning P, Inderjeeth CA (2011) Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporotic treatment in determining patient adherence: a critical review of published articles from 1970-2009. Osteoporos Int 22:741–753CrossRef Lee S, Glendenning P, Inderjeeth CA (2011) Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporotic treatment in determining patient adherence: a critical review of published articles from 1970-2009. Osteoporos Int 22:741–753CrossRef
9.
Zurück zum Zitat Lemstra M, Nwankwo C, Bird Y, Moraros J (2018) Primary nonadherence to chronic disease medications: a meta-analysis. Patient Prefer Adherence 12:721–731CrossRef Lemstra M, Nwankwo C, Bird Y, Moraros J (2018) Primary nonadherence to chronic disease medications: a meta-analysis. Patient Prefer Adherence 12:721–731CrossRef
11.
Zurück zum Zitat Rolnick SJ, Pawloski RA, Hedblom BD, Asche SE, Bruzek RJ (2012) Patient characteristics associated with medication adherence. Clin Med Res 11(2):54–65CrossRef Rolnick SJ, Pawloski RA, Hedblom BD, Asche SE, Bruzek RJ (2012) Patient characteristics associated with medication adherence. Clin Med Res 11(2):54–65CrossRef
12.
Zurück zum Zitat Adachi J, Lynch N, Middelhoven H, Hunjan M, Cowell W (2007) The association between compliance and persistence with bisphosphonate therapy and fracture risk: a review. BMC Musculoskelet Disord 8:97CrossRef Adachi J, Lynch N, Middelhoven H, Hunjan M, Cowell W (2007) The association between compliance and persistence with bisphosphonate therapy and fracture risk: a review. BMC Musculoskelet Disord 8:97CrossRef
13.
Zurück zum Zitat Kelly TL (1990) Bone mineral density databases for American men and women. J Bone Miner Res 5(suppl 2):S249 Kelly TL (1990) Bone mineral density databases for American men and women. J Bone Miner Res 5(suppl 2):S249
14.
Zurück zum Zitat Kanis JA, Adachi JD, Cooper C, Clark P, Cummings SR, Diaz-Curiel M, Harvey N, Hiligsmann M, Papaioannou A, Pierroz DD, Silverman SL, Szulc P (2013) Standardising the descriptive epidemiology of osteoporosis: recommendations from the epidemiology and quality of life working group of IOF. Osteoporos Int 24(11):2763–2764CrossRef Kanis JA, Adachi JD, Cooper C, Clark P, Cummings SR, Diaz-Curiel M, Harvey N, Hiligsmann M, Papaioannou A, Pierroz DD, Silverman SL, Szulc P (2013) Standardising the descriptive epidemiology of osteoporosis: recommendations from the epidemiology and quality of life working group of IOF. Osteoporos Int 24(11):2763–2764CrossRef
15.
Zurück zum Zitat Kildemoes HW, Sørensen HT, Hallas J (2011) The Danish National Prescription Registry. Scand J Public Health 39:38–41CrossRef Kildemoes HW, Sørensen HT, Hallas J (2011) The Danish National Prescription Registry. Scand J Public Health 39:38–41CrossRef
16.
Zurück zum Zitat Lynge E, Sandegaard JL, Rebolj M (2011) The Danish National Patient Register. Scand J Public Health 39:30–33CrossRef Lynge E, Sandegaard JL, Rebolj M (2011) The Danish National Patient Register. Scand J Public Health 39:30–33CrossRef
17.
Zurück zum Zitat Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sørensen HT (2011) The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol 11. https://doi.org/10.1186/1471-2288-11-83 Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sørensen HT (2011) The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol 11. https://​doi.​org/​10.​1186/​1471-2288-11-83
19.
Zurück zum Zitat Rossini ML, Bianchi G, Di Munno O, Giannini S, Minisola S, Sinigaglia L, Adami S (2006) Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 17(6):914–921CrossRef Rossini ML, Bianchi G, Di Munno O, Giannini S, Minisola S, Sinigaglia L, Adami S (2006) Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 17(6):914–921CrossRef
20.
Zurück zum Zitat Penning-van Beest FJ, Erkens JA, Olson M, Herings RM (2008) Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis. Curr Med Res Opin 24(5):1337–1344CrossRef Penning-van Beest FJ, Erkens JA, Olson M, Herings RM (2008) Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis. Curr Med Res Opin 24(5):1337–1344CrossRef
21.
Zurück zum Zitat Jones TJ, Petrella RJ, Crilly R (2008) Determinants of persistence with weekly bisphosphonates in patients with osteoporosis. J Rheumatol 35(9):1865–1873PubMed Jones TJ, Petrella RJ, Crilly R (2008) Determinants of persistence with weekly bisphosphonates in patients with osteoporosis. J Rheumatol 35(9):1865–1873PubMed
22.
Zurück zum Zitat Ideguchi H, Ohno S, Hattori H, Ishigatsubo Y (2007) Persistence with bisphosphonate therapy including treatment courses with multiple sequential bisphosphonates in the real world. Osteoporos Int 18(10):1421–1427CrossRef Ideguchi H, Ohno S, Hattori H, Ishigatsubo Y (2007) Persistence with bisphosphonate therapy including treatment courses with multiple sequential bisphosphonates in the real world. Osteoporos Int 18(10):1421–1427CrossRef
23.
Zurück zum Zitat Iversen MD, Vora RR, Servi A, Solomon DH (2011) Factors affecting adherence to osteoporosis medications: a focus group approach examining viewpoints of patients and providers. J Geriatr Phys Ther 34(2):72–81PubMedPubMedCentral Iversen MD, Vora RR, Servi A, Solomon DH (2011) Factors affecting adherence to osteoporosis medications: a focus group approach examining viewpoints of patients and providers. J Geriatr Phys Ther 34(2):72–81PubMedPubMedCentral
24.
Zurück zum Zitat van der Zwaard BC, van der Horst HE, Hugtenburg JG (2017) Adherence and persistence of patients using oral bone sparing drugs in primary care. Fam Pract 34(5):525–531CrossRef van der Zwaard BC, van der Horst HE, Hugtenburg JG (2017) Adherence and persistence of patients using oral bone sparing drugs in primary care. Fam Pract 34(5):525–531CrossRef
25.
Zurück zum Zitat Black DM, Rosen CJ (2016) Clinical Practice. Postmenopausal Osteoporosis. N Engl J Med 374(3):254–262CrossRef Black DM, Rosen CJ (2016) Clinical Practice. Postmenopausal Osteoporosis. N Engl J Med 374(3):254–262CrossRef
26.
Zurück zum Zitat Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster J-Y (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23–57CrossRef Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster J-Y (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23–57CrossRef
27.
Zurück zum Zitat Hall SF, Edmonds SW, Lou Y, Cram P, Roblin DW, Saag KG, Wright NC, Jones MP, Wolinsky FD (2017) Patient-reported reasons for nonadherence to recommended osteoporosis pharmacotherapy. J Am Pharm Assoc (2003) 57(4):503–509 Hall SF, Edmonds SW, Lou Y, Cram P, Roblin DW, Saag KG, Wright NC, Jones MP, Wolinsky FD (2017) Patient-reported reasons for nonadherence to recommended osteoporosis pharmacotherapy. J Am Pharm Assoc (2003) 57(4):503–509
28.
Zurück zum Zitat Fardellone P, Lello S, Cano A, de Sá ME, Watanabe de Oliveira R, Julian GS, Tang B (2019) Real-world adherence and persistence with bisphosphonate therapy in postmenopausal women:a systematic review. Clin Ther 41(8):1576–1588CrossRef Fardellone P, Lello S, Cano A, de Sá ME, Watanabe de Oliveira R, Julian GS, Tang B (2019) Real-world adherence and persistence with bisphosphonate therapy in postmenopausal women:a systematic review. Clin Ther 41(8):1576–1588CrossRef
29.
Zurück zum Zitat Pepe J, Cipriani C, Cecchetti V, Ferrara C, Della Grotta G, Danese V, Colangelo L, Minisola S (2019) Patients' reasons for adhering to long-term alendronate therapy. Osteoporos Int 30(8):1627–1634CrossRef Pepe J, Cipriani C, Cecchetti V, Ferrara C, Della Grotta G, Danese V, Colangelo L, Minisola S (2019) Patients' reasons for adhering to long-term alendronate therapy. Osteoporos Int 30(8):1627–1634CrossRef
30.
Zurück zum Zitat Alswat K, Adler SM (2012) Gender differences in osteoporosis screening: retrospective analysis. Arch Osteoporos 7:311–313CrossRef Alswat K, Adler SM (2012) Gender differences in osteoporosis screening: retrospective analysis. Arch Osteoporos 7:311–313CrossRef
31.
Zurück zum Zitat Sawka AM, Adachi JD, Papaioannou A, Thabane L, Ioannidis G, Davison KS, Olszynski WP, Brown JP, Hanley DA, Murray TM, Josse RG, Sebaldt RJ, Petrie A, Tenenhouse A, Goldsmith CH (2004) Are there differences between men and women prescribed bisphosphonate therapy in Canadian subspecialty osteoporosis practices? J Rheumatol 31:1993–1995PubMed Sawka AM, Adachi JD, Papaioannou A, Thabane L, Ioannidis G, Davison KS, Olszynski WP, Brown JP, Hanley DA, Murray TM, Josse RG, Sebaldt RJ, Petrie A, Tenenhouse A, Goldsmith CH (2004) Are there differences between men and women prescribed bisphosphonate therapy in Canadian subspecialty osteoporosis practices? J Rheumatol 31:1993–1995PubMed
32.
Zurück zum Zitat Schneider DL, Bettencourt R, Barrett-Connor E (2006) Clinical utility of spine bone density in elderly women. J Clin Densitom 3:255–260CrossRef Schneider DL, Bettencourt R, Barrett-Connor E (2006) Clinical utility of spine bone density in elderly women. J Clin Densitom 3:255–260CrossRef
Metadaten
Titel
Outcome of osteoporosis evaluation, treatment, and follow-up in patients referred to a specialized outpatient clinic compared to patients in care of general practitioners
verfasst von
Mette Friberg Hitz
Sofie Arup
Jakob Praest Holm
Anne Lyngholm Soerensen
Thomas Alexander Gerds
Jens-Erik Beck Jensen
Publikationsdatum
01.12.2020
Verlag
Springer London
Erschienen in
Archives of Osteoporosis / Ausgabe 1/2020
Print ISSN: 1862-3522
Elektronische ISSN: 1862-3514
DOI
https://doi.org/10.1007/s11657-020-00774-9

Weitere Artikel der Ausgabe 1/2020

Archives of Osteoporosis 1/2020 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.